the acorda therapeutics organization is a neurospecialty organization that is a neurospecialty organization that has been recognized for its creative approaches to serve the needs in the multiple sclerosis community and also to risk sharing and reimbursement. we have achieved a number of key milestones in 2017. we reported a 10% increase over 2016. we achieved a number of key milestones in the year. we reported a number of key milestones in 2017 and we reported a number of key milestones. we have been encouraging by the trends we see in the overall movement disorder space with new entrance into the market and market research on this technology. we expect a number of key milestones clinically and corporate in-2018. we expect a number of key steps in the development and development of a new drug. we expect a number of key achievements in the year. we expect a number of key landmarks in 2018. we expect a number of key key milestones in 2018. we expect a large number of key milestones in 2018. we expect the number of key milestones in 2018 are expected to be 330 million to 350 million. we expect a number of key progresses in the future.